Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Active not recruiting 2Withdrawn 1Unknown 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 2

Conditions

Glioblastoma 41Glioma 10Brain Neoplasms 9Gliosarcoma 8Astrocytoma 7Neuroblastoma 6Small Cell Lung Carcinoma 4Oligodendroglioma 4Neoplasms 4Medulloblastoma 4Sarcoma, Ewing 3Sarcoma 3Melanoma 3Somatostatinoma 2Rhabdomyosarcoma 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Neuroendocrine Tumors 2Lung Neoplasms 2Ependymoma 2Diffuse Intrinsic Pontine Glioma 2Desmoplastic Small Round Cell Tumor 2Central Nervous System Neoplasms 2Carcinoma, Neuroendocrine 2Adenoma, Islet Cell 2Supratentorial Neoplasms 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Prostatic Neoplasms 1

Interventions

Specimen Handling 3Temozolomide 2Magnetic Resonance Spectroscopy 2tipifarnib 1talazoparib 1pembrolizumab 1olaparib 1lutetium Lu 177 dotatate 1lanreotide 1copper dotatate CU-64 1Staining and Labeling 1Nivolumab 1Lutetium-177 1Lutetium 1Ipilimumab 1Contrast Media 1CTLA-4 Antigen 1Biopsy 1Axitinib 16-fluorodopamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Pheochromocytoma × Temozolomide × Clear all
NCT04394858 2026-05-13

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
46 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05142241 2025-11-18

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
14 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡